Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $121.99 million
- Book Value:
- Revenue TTM:
- $72.05 million
- Operating Margin TTM:
- Gross Profit TTM:
- $42.80 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Chromadex Corp had its IPO on 2008-07-15 under the ticker symbol CDXC.
The company operates in the Healthcare sector and Biotechnology industry. Chromadex Corp has a staff strength of 113 employees.
Shares of Chromadex Corp opened at $1.6 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $1.54 - $1.62, and closed at $1.58.
This is a -3.07% slip from the previous day's closing price.
A total volume of 321,300 shares were traded at the close of the day’s session.
In the last one week, shares of Chromadex Corp have slipped by -3.66%.
Chromadex Corp's Key Ratios
Chromadex Corp has a market cap of $121.99 million, indicating a price to book ratio of 5.4905 and a price to sales ratio of 1.7315.
In the last 12-months Chromadex Corp’s revenue was $72.05 million with a gross profit of $42.80 million and an EBITDA of $-17573000. The EBITDA ratio measures Chromadex Corp's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Chromadex Corp’s operating margin was -25.85% while its return on assets stood at -20.81% with a return of equity of -54.77%.
In Q4, Chromadex Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 18.2%.
Chromadex Corp’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.24 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Chromadex Corp’s profitability.
Chromadex Corp stock is trading at a EV to sales ratio of 1.5512 and a EV to EBITDA ratio of -5.7396. Its price to sales ratio in the trailing 12-months stood at 1.7315.
Chromadex Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $54.06 million
- Total Liabilities
- $17.87 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Chromadex Corp ended 2023 with $54.06 million in total assets and $0 in total liabilities. Its intangible assets were valued at $54.06 million while shareholder equity stood at $28.67 million.
Chromadex Corp ended 2023 with $0 in deferred long-term liabilities, $17.87 million in other current liabilities, 74000.00 in common stock, $-185493000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $20.44 million and cash and short-term investments were $20.44 million. The company’s total short-term debt was $696,000 while long-term debt stood at $0.
Chromadex Corp’s total current assets stands at $46.57 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $8.48 million compared to accounts payable of $9.68 million and inventory worth $14.68 million.
In 2023, Chromadex Corp's operating cash flow was $-172000.00 while its capital expenditure stood at $0.
Comparatively, Chromadex Corp paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Chromadex Corp stock is currently trading at $1.58 per share. It touched a 52-week high of $2.99 and a 52-week low of $2.99. Analysts tracking the stock have a 12-month average target price of $5.55.
Its 50-day moving average was $1.82 and 200-day moving average was $1.69 The short ratio stood at 9.78 indicating a short percent outstanding of 0%.
Around 4187.9% of the company’s stock are held by insiders while 1557.9% are held by institutions.
Frequently Asked Questions About Chromadex Corp
Similar Industry Stocks (Biotechnology)
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.